Navigation Links
NeoStem to Present at Third Annual Stem Cell Summit in New York City
Date:2/26/2008

NEW YORK, Feb. 26 /PRNewswire-FirstCall/ -- NeoStem, Inc. (Amex: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, today announced that the Company is scheduled to present at the 3rd Annual Stem Cell Summit in New York City on Tuesday, February 26, 2008.

The Annual Stem Cell Summit is organized and produced by RRY Publications and Robin Young Consulting. This year's Summit will feature more than 50 speakers, including a panel of stem cell patients. The goal of the Summit is to bring together investors, industry executives, practitioners and analysts to learn about investment opportunities in the stem cell marketplace, groundbreaking stem cell products physicians are using today, and the growing market potential in terms of revenues. For additional information or to register, please visit http://www.stemcellsummit.com.

Wayne A. Marasco, MD, Ph.D., NeoStem Inc. Cofounder and Chairman of the Scientific Advisory Board will give a brief presentation on the Company's proprietary Very Small Embryonic Like Stem Cells (VSELs) technology. VSELs have been identified in adult bone marrow and resemble embryonic stem cells both morphologically and transcriptionally. Although early stage technology, the Company expects VSELS to serve as the basis for its entry into the therapeutic market place.

VSELs have the ability to grow in the laboratory and multiply into clusters of cells that then can differentiate into specialized cells found in different types of tissue including cardiac, neural, endothelial, muscle, pancreatic and hematopoietic cells. However, unlike controversial embryonic stem cells, VSELs can be harvested from adult peripheral blood. These naturally occurring regenerative cells may have the potential to be used for future therapeutic repair of degenerative, diseased or damaged tissue.

About NeoStem, Inc.

NeoStem is managing a growing nationwide network of adult stem cell collection centers, enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also recently entered the research and development and therapeutic arenas, through the acquisition of a worldwide exclusive license to an early-stage technology to identify and isolate rare stem cells from adult human bone marrow, called VSELs (very small embryonic- like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business, to develop the VSEL technology, the future of regenerative medicine and the role of adult stem cells and VSELs in that future, the future use of adult stem cells and VSELs as a treatment option and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena, its success in such arena and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to obtain sufficient capital or a strategic business arrangements to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) scientific and medical developments beyond the Company's control; (v) the Company's inability to obtain appropriate state licenses or any other adverse effect or limitations caused by government regulation of the business; (vi) whether any of the Company's current or future patent applications result in issued patents; and (vii) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission.

Contact:

NeoStem, Inc.

Robin Smith, Chief Executive Officer, 212-584-4180

rsmith@neostem.com

http://www.neostem.com


'/>"/>
SOURCE NeoStem, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NeoStem Announces NY State License for Adult Stem Cell Collection
2. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
3. Avicena Group to Present at Noble Financial Conference
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
6. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
7. CEL-SCI to Present at the Noble Financial Conference
8. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
9. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
10. Strategic Diagnostics Updates Roth Conference Presentation Time
11. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , ... March 27, 2017 , ... ... accelerating the fight against cancer, autoimmune disease and more through a single-cell precision ... metabolomics and proteomics analysis platform developed in the laboratory of Dr. James ...
(Date:3/27/2017)... Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), today announced positive results of ... in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 is a new small molecule drug ... National Institutes of Health. Continue Reading ... ... ...
(Date:3/27/2017)... The new research portal will give ... reports on Valero Energy , offering extensive market research ... ... (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO) The latest trend gaining ... Ethanol today, even though touted as a green alternative to ...
(Date:3/27/2017)... -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, ... Welch , will be presenting at this year,s MicroCap ... at the Essex House in New York ... Mark Erlander , Ph.D., will also be available ... The presentation will be webcast live at http://wsw.com/webcast/microcapconf3/trov ...
Breaking Biology Technology:
(Date:3/22/2017)... YORK , March 21, 2017 ... Marketing Cloud used by retailers such as 1-800-Flowers ... its platform — Product Recommendations and Replenishment. Using Optimove,s ... give more personalized product and replenishment recommendations to ... but also on predictions of customer intent drawn ...
(Date:3/13/2017)... March 13, 2017 Future of security: Biometric Face Matching ... ... DERMALOGs Face Matching enables to match face pictures against each ... to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face Matching on ...
(Date:3/6/2017)... , March 6, 2017 Mintigo ... technology, today announced Predictive Sales Coach TM , ... actionable sales intelligence into Salesforce. This unique AI ... their sales organizations with deep knowledge of their ... for intelligent engagement. Predictive Sales Coach extends Mintigo,s ...
Breaking Biology News(10 mins):